(vianews) - the market ended the session with abivax (abvx.pa) jumping 9.79% to €14.80 on thursday, after three sequential sessions in a row of losses. cac 40 dropped 0.27% to €8,023.74, after two sequential sessions in a row of losses, on what was a somewhat negative trend trading session today.
abivax's last close was €13.48, 31.57% under its 52-week high of €19.70.
about abivax
abivax société anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. the company is evaluating its lead drug candidate, obefazimod, in phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. abivax société anonyme was incorporated in 2013 and is headquartered in paris, france.
earnings per share
as for profitability, abivax has a trailing twelve months eps of €-2.43.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -211.42%.
volume
today's last reported volume for abivax is 69951 which is 104.85% above its average volume of 34147.
volatility
abivax's last week, last month's, and last quarter's current intraday variation average was a negative 1.07%, a positive 0.35%, and a positive 2.62%.
abivax's highest amplitude of average volatility was 1.43% (last week), 1.62% (last month), and 2.62% (last quarter).
more news about abivax (abvx.pa).